読み込み中
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
通常取引
$43.64
−$1.90 · -4.17%
日中の時刻はETです。市場データは遅延する場合があります。
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
日中レンジ
現在 $43.64
52週レンジ
現在 $43.64
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
44
適正価値
センチメント
63
強気
リスク
88
極めて高いリスク
モメンタム
23
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
日中レンジ
現在 $43.64
52週レンジ
現在 $43.64
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | 491.1万 USD | 1008.9万 USD | — | — |
| 粗利益 | — | 491.1万 USD | 1008.9万 USD | — | — |
| 研究開発 | 1952.2万 USD | 4641.8万 USD | 4943.2万 USD | 3519.8万 USD | 3069.8万 USD |
| 販売・一般管理 | 1699.1万 USD | 1464.4万 USD | 1265万 USD | 1208.5万 USD | 1136.8万 USD |
| 営業費用 | 3651.3万 USD | 6106.2万 USD | 6208.2万 USD | 4728.3万 USD | 4206.6万 USD |
| 受取利息 | 113.7万 USD | 342.2万 USD | 455.7万 USD | 152.3万 USD | 11.9万 USD |
| 支払利息 | 9万 USD | 30.7万 USD | 48.3万 USD | 42万 USD | 34.5万 USD |
| 減価償却費と償却費 | 2.1万 USD | 4.6万 USD | 7万 USD | 7.4万 USD | 6.8万 USD |
| 営業利益 | −3651.3万 USD | −5615.1万 USD | −5199.3万 USD | −4728.3万 USD | −4206.6万 USD |
| 純利益 | −3896.6万 USD | −5303.6万 USD | −4791.9万 USD | −4618万 USD | −4229.2万 USD |
会社概要が更新されました 2026年10月9日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI500.86万0.00%2.3兆 USD0.03%$381.16+0.42%
iShares Russell 2000 ETFIWM319.4万0.00%776.97億 USD0.19%$278.74+0.42%
Vanguard Extended Market ETFVXF188.07万0.00%954億 USD0.05%$234.62+0.64%
Vanguard Russell 2000 ETFVTWO91.98万0.01%180億 USD0.06%$112.59+0.43%
iShares Russell 2000 Value ETFIWN80.24万0.01%137.55億 USD0.24%$211.02+0.03%
iShares Micro-Cap ETFIWC35.52万0.03%13.19億 USD0.60%$182.91+0.06%
iShares Russell 2000 Growth ETFIWO29.63万0.00%140.44億 USD0.24%$356.11+0.75%
Dimensional - US Small Cap ETFDFAS18万0.00%337.96億 USD0.31%$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Value ETFIWNiShares Micro-Cap ETFIWCiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
